Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company covers the date of March 21, 2007. The report addresses a specific regulatory event under Item 8.01 (Other Events) involving federal investigations into a proposed patent settlement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statement data.
Material Changes
There are no financial material changes reported in this document. The material event is the receipt of a Civil Investigative Demand (CID) from the U.S. Federal Trade Commission (FTC) on March 21, 2007. The CID requests documents and information regarding the proposed settlement with Apotex in the Plavix patent litigation pending in the U.S. District Court for the Southern District of New York.
Outlook, Risks, and Contingencies
- FTC Investigation: The Company intends to cooperate fully with the FTC investigation triggered by the CID.
- DOJ Investigation: The Company is also cooperating with a previously disclosed criminal investigation by the Antitrust Division of the U.S. Department of Justice regarding the same proposed settlement.
- Outcome Assessment: Management states it is not possible at this time to reasonably assess the outcome of either the FTC or DOJ investigations or their potential impact on the Company.
- Reference: Further details on the underlying patent litigation and the DOJ investigation are referenced in the Company's 2006 Annual Report on Form 10-K, Note 21 (Legal Proceedings and Contingencies).
Investor Verification Checklist
- Verify the status of the Plavix patent litigation with Apotex in the U.S. District Court for the Southern District of New York.
- Review the 2006 Form 10-K, Note 21, for historical context on the DOJ criminal investigation and the proposed settlement terms.
- Monitor future disclosures for updates on the FTC Civil Investigative Demand and any resulting regulatory actions.
- Assess the potential financial impact of the investigations on the Company's legal contingencies and future revenue from Plavix.